Modified factor VIII
AssigneeEmory University
InventorJohn S. Lollar
Life of this patent
Estimating the term…
Abstract
Site-specific replacement of amino acids in the region of positions 484-509 of human factor VIII can result in reduction of reactivity to an inhibitory antibody while procoagulant activity is retained. Modified human factor VIII having an immunoreactivity-reducing amino acid substituted for the naturally occurring amino acid is described.
Claims22
Modified human factor VIII comprising an amino acid substitution at one or more of position 484, 485, 487, 488, 489, 492, 495, 501 or 508, according to SEQ ID NO:2, said substitution being insertion of an immunoreactivity-reducing amino acid for the naturally-occurring amino acid, said modified factor VIII having procoagulant activity.
A method for modifying a factor VIII such that reactivity to an inhibitory antibody is reduced and procoagulant activity is retained, consisting essentially of substituting an immunoreactivity-reducing amino acid for the naturally-occurring amino acid at least one of positions 484, 485, 487, 488, 489, 492, 495, 501, or 508 according to SEQ ID NO:2.
Dependencies are inferred from the claim text.